Literature DB >> 12369064

Superbugs II: how should economic evaluation be conducted for interventions which aim to contain antimicrobial resistance?

Joanna Coast1, Richard Smith, Anne-Marie Karcher, Paula Wilton, Michael Millar.   

Abstract

To date, there has been little examination of the problems associated with conducting economic evaluation for interventions designed to contain antimicrobial resistance. There are two quite different types of intervention aimed at containing antimicrobial resistance: interventions which are designed to avoid the emergence of resistant organisms; and interventions that are designed to avoid the transmission of resistance organisms. Four aspects of economic evaluation where the ease of assessment might be expected to differ across evaluations for these different types of intervention are examined: problems associated with the identification of diffuse impacts, problems associated with comparing current and future impacts, problems associated with uncertainty, and problems associated with difficulties in measurement and valuation. The paper suggests that it may be much easier to conduct rigorous economic evaluations for interventions designed to avoid transmission of resistance, than for those intended to avoid emergence. Unfortunately, the transmission policies, which are likely to be the easiest to evaluate, are not likely to produce an optimal long-term outcome given the apparent irreversibility of much resistance and the potentially severe harms which could be imposed as a result. Given the desirability of avoiding a scenario where, in the evidence-based medicine culture, the most rigorously evaluated policies are followed even though they may be less important, there is the need to consider carefully what, and how, economic evaluation should be conducted in the area of antimicrobial resistance. It is suggested that research should focus on the use of modelling as a means of evaluating optimal policy responses and on trying to resolve some of the difficulties associated with measurement and valuation. Copyright 2002 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2002        PMID: 12369064     DOI: 10.1002/hec.693

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  11 in total

Review 1.  Economic aspects of pneumococcal pneumonia: a review of the literature.

Authors:  Diana De Graeve; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 2.  Bacterial resistance: a sensitive issue complexity of the challenge and containment strategy in Europe.

Authors:  W T M Jansen; J T van der Bruggen; J Verhoef; A C Fluit
Journal:  Drug Resist Updat       Date:  2006-06-27       Impact factor: 18.500

3.  Economic evaluations of neuraminidase inhibitors to control influenza.

Authors:  Michaël Schwarzinger; Karine Lacombe; Fabrice Carrat
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2003-04       Impact factor: 2.217

Review 4.  How externalities impact an evaluation of strategies to prevent antimicrobial resistance in health care organizations.

Authors:  Jenine R Leal; John Conly; Elizabeth Ann Henderson; Braden J Manns
Journal:  Antimicrob Resist Infect Control       Date:  2017-06-02       Impact factor: 4.887

5.  Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use.

Authors:  Poojan Shrestha; Ben S Cooper; Joanna Coast; Raymond Oppong; Nga Do Thi Thuy; Tuangrat Phodha; Olivier Celhay; Philippe J Guerin; Heiman Wertheim; Yoel Lubell
Journal:  Antimicrob Resist Infect Control       Date:  2018-08-09       Impact factor: 4.887

6.  Optimal subscription models to pay for antibiotics.

Authors:  Euan Barlow; Alec Morton; Itamar Megiddo; Abigail Colson
Journal:  Soc Sci Med       Date:  2022-02-16       Impact factor: 4.634

7.  Quality of life, healthcare use and costs in 'at-risk' children after early antibiotic treatment versus placebo for influenza-like illness: within-trial descriptive economic analyses of the ARCHIE randomised controlled trial.

Authors:  Ines Rombach; Kay Wang; Sharon Tonner; Jenna Grabey; Anthony Harnden; Jane Wolstenholme
Journal:  BMJ Open       Date:  2022-04-15       Impact factor: 3.006

8.  Antimicrobial guidelines in clinical practice: incorporating the ethical perspective.

Authors:  Merel Lambregts; Babette Rump; Fabienne Ropers; Martijn Sijbom; Mariska Petrignani; Leo Visser; Martine de Vries; Mark de Boer
Journal:  JAC Antimicrob Resist       Date:  2021-07-02

9.  Cost effectiveness of antimicrobial catheters in the intensive care unit: addressing uncertainty in the decision.

Authors:  Kate A Halton; David A Cook; Michael Whitby; David L Paterson; Nicholas Graves
Journal:  Crit Care       Date:  2009-03-11       Impact factor: 9.097

10.  Modelling the Impact and Cost-Effectiveness of Biomarker Tests as Compared with Pathogen-Specific Diagnostics in the Management of Undifferentiated Fever in Remote Tropical Settings.

Authors:  Yoel Lubell; Thomas Althaus; Stuart D Blacksell; Daniel H Paris; Mayfong Mayxay; Wirichada Pan-Ngum; Lisa J White; Nicholas P J Day; Paul N Newton
Journal:  PLoS One       Date:  2016-03-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.